BofA Securities resumed coverage on Cardlytics with a new price target
$CDLX
Computer Software: Programming Data Processing
Technology
BofA Securities resumed coverage of Cardlytics with a rating of Neutral and set a new price target of $11.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/11/2024 | $4.00 | In-line | Evercore ISI |
| 8/16/2024 | $5.00 | Outperform → Market Perform | Northland Capital |
| 8/15/2024 | $4.00 → $3.50 | Neutral → Underperform | BofA Securities |
| 8/8/2024 | Buy → Hold | Craig Hallum | |
| 8/8/2024 | Buy → Hold | Needham | |
| 8/8/2024 | $18.00 → $5.00 | Buy → Hold | Lake Street |
| 6/20/2024 | $11.00 | Neutral | BofA Securities |
| 6/18/2024 | $14.00 | Outperform | Northland Capital |
SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio
ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced that the Board of Directors has appointed Amit Gupta, Chief Operating Officer and General Manager of Bridg, as its next Chief Executive Officer of Cardlytics, effective August 16, 2024. He will also join the Cardlytics Board of Directors on that date. Mr. Gupta will succeed Karim Temsamani, who is stepping down as Chief Executive Officer and from the Board of Directors to pursue another professional opportunity. "Amit is the right person to lead Cardlytics in its next stage of growth," said Jack Klinck, Chair of the Cardlytics Board. "For the last year and a half, Ami
ATLANTA, April 09, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, is excited to announce the appointment of Liane Hornsey to its Board of Directors. In connection with her appointment to the Board of Directors, Hornsey was also appointed to the Board's Compensation Committee, and she will assume the role of Compensation Committee Chairperson upon Cardlytics' upcoming Annual Meeting of Stockholders in May 2024. Hornsey, who is currently Executive Vice President and Advisor to the CEO at Palo Alto Networks, is widely recognized as one of the world's top practitioners in people operations, organizational development and leadership development. She jo
4 - Cardlytics, Inc. (0001666071) (Issuer)
4 - Cardlytics, Inc. (0001666071) (Issuer)
4 - Cardlytics, Inc. (0001666071) (Issuer)
S-8 - Cardlytics, Inc. (0001666071) (Filer)
10-Q - Cardlytics, Inc. (0001666071) (Filer)
8-K - Cardlytics, Inc. (0001666071) (Filer)
SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)
SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)
SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)
B of A Securities analyst Omar Dessouky reinstates Cardlytics (NASDAQ:CDLX) with a Neutral and announces $11 price target.
Northland Capital Markets analyst Luke Horton initiates coverage on Cardlytics (NASDAQ:CDLX) with a Outperform rating and announces Price Target of $14.
4 - Cardlytics, Inc. (0001666071) (Issuer)
4 - Cardlytics, Inc. (0001666071) (Issuer)
3 - Cardlytics, Inc. (0001666071) (Issuer)
ATLANTA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ:CDLX), an advertising platform in banks' digital channels, today announced that its financial results for the third quarter ending September 30, 2024 will be released on November 6, 2024, after market close. The results will be discussed via conference call at 5:00 PM ET / 2:00 PM PT. The company invites investors to join a live audio webcast at http://ir.cardlytics.com/ or to dial-in by registering at this link. A replay will be available on the Cardlytics Investor Relations website at http://ir.cardlytics.com/. About Cardlytics Cardlytics (NASDAQ:CDLX) is a digital advertising platform. We partner with financial insti
ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced financial results for the second quarter ended June 30, 2024. "We continue to believe in the significant growth opportunity as we invest to modernize our platform. We are making progress, but transitions like this take time and these near-term challenges do not change the long-term potential of this business," said Amit Gupta, incoming CEO of Cardlytics. "We have the right team and right strategy in place to deliver stronger execution and shareholder value as we continue this transformation. The strong advertiser demand, the addition of new partners and the high c
ATLANTA, July 24, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ:CDLX), an advertising platform in banks' digital channels, today announced that its second quarter ended June 30, 2024 financial results will be released on August 7, 2024, after market close. The results will be discussed via conference call at 5:00 PM (ET) / 2:00 PM (PT). The company invites investors to join a live audio webcast at http://ir.cardlytics.com/ or to dial-in by registering at this link. A replay will be available on the Cardlytics Investor Relations website at http://ir.cardlytics.com/. About Cardlytics Cardlytics (NASDAQ:CDLX) is a digital advertising platform. We partner with financial institutions
SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio
ATLANTA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ:CDLX), an advertising platform in banks' digital channels, today announced that its financial results for the third quarter ending September 30, 2024 will be released on November 6, 2024, after market close. The results will be discussed via conference call at 5:00 PM ET / 2:00 PM PT. The company invites investors to join a live audio webcast at http://ir.cardlytics.com/ or to dial-in by registering at this link. A replay will be available on the Cardlytics Investor Relations website at http://ir.cardlytics.com/. About Cardlytics Cardlytics (NASDAQ:CDLX) is a digital advertising platform. We partner with financial insti
ATLANTA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ: CDLX), an advertising platform in banks' digital channels, today announced that, on August 19, 2024, the Compensation Committee of Cardlytics' Board of Directors granted an aggregate of 49,900 restricted stock units of Cardlytics to seven newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the "2022 Inducement Plan"). For all of the grant recipients, 50% of the restricted stock units shall vest on the first anniversary of the grant date, and t
Evercore ISI initiated coverage of Cardlytics with a rating of In-line and set a new price target of $4.00
Northland Capital downgraded Cardlytics from Outperform to Market Perform and set a new price target of $5.00
BofA Securities downgraded Cardlytics from Neutral to Underperform and set a new price target of $3.50 from $4.00 previously